haloperidol decanoate has been researched along with fluphenazine in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (30.77) | 18.7374 |
| 1990's | 8 (30.77) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 6 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cho, YS; Hwang, EM; Jung, SY; Lim, SM; Min, SJ; Pae, AN; Park, KD; Viswanath, AN | 1 |
| Cookson, JC | 1 |
| Kalugina, LI; Kopeĭko, GI; Kravchenko, NE; Mirzoian, MG; Ushakov, IuV | 1 |
| McCreadie, RG; Whitehead, A; Wiles, DH | 1 |
| Annable, L; Campbell, W; Chouinard, G | 1 |
| Knudsen, P | 1 |
| James, WA; Pary, R; Tobias, CR; Turns, DM | 1 |
| McCreadie, RG; McKane, JP; Robinson, AD; Stirling, GS; Wiles, DH | 1 |
| Wistedt, B | 1 |
| Cookson, JC; Gribbon, D; Kennedy, NM | 1 |
| Kissling, W; Krueger, R; Möller, HJ; Trenk, D; Walter, K; Wittmann, B | 1 |
| Annable, L; Boisvert, D; Bradwejn, J; Campbell, W; Chouinard, G | 1 |
| Amico, E; Goff, DC; Hubbard, JW; Midha, KK; Sarid-Segal, O | 1 |
| Baruah, S; Sherman, A; Waziri, R | 1 |
| Brauzer, B; Casey, DE; Davis, JM; Gierl, B; Hassan, M; Kane, JM; Marder, SR; Schooler, N | 1 |
| Dhopesh, V; Gamble, G; Maany, I; Macfadden, A | 1 |
| Conley, RR; Kelly, DL; Love, RC; Moore, DB; Sherr, JD | 1 |
| Chengappa, KN; Jeste, DV; Mamo, DC; Reddy, RR; Sweet, RA | 1 |
| Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M | 1 |
| McEvoy, JP | 1 |
| Ascher-Svanum, H; Faries, D; Marder, SR; Montgomery, W; Shi, L; Zhu, B | 1 |
| Citrome, L; Jaffe, A; Levine, J | 1 |
| Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS | 1 |
| Bellaaj, R; Bouguerra, C; Gallali, S; Mehdi, F; Oumaya, A; Sejil, I | 1 |
| Den, R; Mimura, M; Sakurai, H; Suzuki, T; Tsutsumi, C; Uchida, H; Uchida, T | 1 |
3 review(s) available for haloperidol decanoate and fluphenazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dose response of prophylactic antipsychotics.
Topics: Administration, Oral; Aftercare; Antipsychotic Agents; Combined Modality Therapy; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluphenazine; Haloperidol; Humans; Patient Compliance; Psychotherapy; Recurrence; Schizophrenia; Schizophrenic Psychology | 1993 |
Risks versus benefits of different types of long-acting injectable antipsychotics.
Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Haloperidol; Health Care Costs; Humans; Injections, Intramuscular; Microspheres; Quality of Life; Risk Assessment; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Refusal | 2006 |
12 trial(s) available for haloperidol decanoate and fluphenazine
| Article | Year |
|---|---|
Side effects during long-term treatment with depot antipsychotic medication.
Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Fluphenazine; Haloperidol; Humans; Parkinson Disease, Secondary; Psychomotor Agitation; Recurrence; Schizophrenia | 1991 |
[Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Fluphenazine; Haloperidol; Humans; Remission Induction; Schizophrenia | 1990 |
Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Topics: Adult; Aged; Biological Availability; Double-Blind Method; Female; Fluphenazine; Half-Life; Haloperidol; Humans; Male; Middle Aged; Prolactin; Radioimmunoassay; Schizophrenia | 1990 |
A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloperidol; Humans; Long-Term Care; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1989 |
Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Random Allocation; Schizophrenia | 1987 |
A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1986 |
Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
Topics: Adult; Body Weight; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Prolactin; Schizophrenia | 1986 |
Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Topics: Adult; Double-Blind Method; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1985 |
A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; Haloperidol; Humans; Male; Schizophrenia | 1984 |
A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Fluphenazine; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1995 |
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Movement Disorders; Psychiatric Status Rating Scales; Risperidone; Schizophrenia | 2004 |
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Hyperprolactinemia; Injections; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Microspheres; Middle Aged; Patient Compliance; Proportional Hazards Models; Risperidone; Schizophrenia; Weight Gain | 2012 |
11 other study(ies) available for haloperidol decanoate and fluphenazine
| Article | Year |
|---|---|
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
Topics: Animals; Computer Simulation; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Mice; Mice, Knockout; Molecular Docking Simulation; Potassium Channels, Tandem Pore Domain | 2016 |
Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
Topics: Administration, Oral; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Flupenthixol; Fluphenazine; Haloperidol; Humans; Kinetics; Long-Term Care; Patient Compliance; Perphenazine; Schizophrenia; Schizophrenic Psychology; Thiazines | 1985 |
Depot neuroleptics for acutely psychotic patients.
Topics: Acute Disease; Antipsychotic Agents; Fluphenazine; Haloperidol; Humans; Psychotic Disorders | 1987 |
Neuroleptic effects on serine and glycine metabolism.
Topics: Adult; Animals; Antipsychotic Agents; Brain; Cytosol; Female; Fluphenazine; Glycine; Glycine Hydroxymethyltransferase; Haloperidol; Humans; Liver; Male; Mitochondria, Liver; Psychiatric Status Rating Scales; Rabbits; Rats; Rats, Sprague-Dawley; Schizophrenia; Schizophrenic Psychology; Serine | 1993 |
Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cocaine; Comorbidity; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Long-Term Care; Male; Middle Aged; Neurologic Examination; Opioid-Related Disorders; Parkinson Disease, Secondary; Receptors, Dopamine; Risk Factors; Schizophrenia | 1997 |
Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Topics: Antipsychotic Agents; Baltimore; Chronic Disease; Delayed-Action Preparations; Disease-Free Survival; Female; Fluphenazine; Haloperidol; Humans; Length of Stay; Male; Patient Readmission; Risperidone; Schizophrenia; Time Factors | 1998 |
The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Prodrugs; Psychotic Disorders; Schizophrenia | 2002 |
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
Topics: Administration, Oral; Adult; Alcoholism; Antipsychotic Agents; Black People; Cohort Studies; Comorbidity; Crime; Cross-Sectional Studies; Delayed-Action Preparations; Drug Utilization; Female; Fluphenazine; Haloperidol; Humans; Illicit Drugs; Male; Middle Aged; Patient Readmission; Prospective Studies; Schizophrenia; Schizophrenia, Disorganized; Schizophrenic Psychology; Substance-Related Disorders; Treatment Outcome; United States; White People | 2007 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Utilization; Female; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Length of Stay; Male; Microspheres; Middle Aged; Patient Discharge; Proportional Hazards Models; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
[Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Movement Disorders; Neurologic Examination; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Surveys and Questionnaires; Tunisia | 2013 |
Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Combinations; Female; Fluphenazine; Haloperidol; Humans; International Classification of Diseases; Longitudinal Studies; Maintenance Chemotherapy; Male; Medical Records; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Secondary Prevention; Treatment Outcome | 2013 |